# FGFR1

Source: https://onco.cc/targets/fgfr1/  
OnCo record `fgfr1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A growth receptor amplified in squamous lung cancer and fused in a rare blood cancer. Pemigatinib is approved for the FGFR1-rearranged myeloid and lymphoid neoplasm, and pan-FGFR drugs block FGFR1 too, which is why they raise blood phosphate.

## Summary

FGFR1 is amplified in a minority of squamous lung and breast cancers and rearranged, most often with ZMYM2 or BCR, in the myeloid or lymphoid neoplasm with eosinophilia and FGFR1 rearrangement, an aggressive disease that responds to pemigatinib, approved for it in 2022. The pan-FGFR inhibitors erdafitinib, pemigatinib and futibatinib all inhibit FGFR1, and because FGFR1 in the kidney controls phosphate excretion, hyperphosphataemia is their shared class effect and dose marker. FGFR1 amplification alone has proved a weak predictor of response to FGFR inhibitors in solid tumours.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: FGFR1
- Class: kinase
- Biology: Receptor tyrosine kinase; gene amplification in squamous cancers and fusions in the 8p11 myeloproliferative syndrome; renal FGFR1 mediates the hyperphosphataemia of pan-FGFR inhibitors.
- Where found: Myeloid or lymphoid neoplasm with FGFR1 rearrangement; Squamous non-small-cell lung cancer (amplification); Hormone receptor-positive breast cancer (amplification); Non-small-cell lung cancer: focal high-level amplification 17-22%

## Notes

- Lung cancer: focally amplified in 17 to 22% of squamous tumours and 2.7% of adenocarcinomas, the first therapeutically tractable alteration found in squamous disease (Weiss 2010; cBioPortal). It is also the standard example of amplification not equalling dependence: amplified cell lines die under FGFR inhibition, and patients selected on copy number alone have responded poorly.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_1
- UniProt P11362: FGFR1: https://www.uniprot.org/uniprotkb/P11362/entry

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Erdafitinib](https://onco.cc/drugs/erdafitinib/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/)
- pathways: [FGF / FGFR signalling](https://onco.cc/pathways/fgfr-signalling/)
- terms: [Gene amplification and copy-number change](https://onco.cc/terms/gene-amplification/)
- key papers: [Androgen receptor pathway-independent prostate cancer is sustained through FGF signalling](https://onco.cc/key-papers/paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017/), [Comprehensive genomic characterization of squamous cell lung cancers](https://onco.cc/key-papers/paper-tcga-lung-squamous-nature-2012/), [Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer](https://onco.cc/key-papers/paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010/)

---
JSON: https://onco.cc/api/v1/entities/fgfr1.json